List of patients tested for PRV-1 expression
| Patient . | Sex . | Age (y) . | Duration of Disease . | Treatment . | LAP (normal: 10-100) . | Diagnosis . | PRV-1 Expression . |
|---|---|---|---|---|---|---|---|
| WZ | F | 75 | 2 y | Phl | nd | PV | +++ |
| EH | F | 68 | 12 y | Phl, HU, Bu | 84 | PV | +++ |
| HJL | M | 59 | 4 y | Phl | 200 | PV | +++ |
| SR | M | 62 | 7 y | Phl | nd | PV | +++ |
| UW | M | 65 | 10 y | Phl, HU | nd | PV | +++ |
| UD | F | 66 | < 1 y | Phl | 264 | PV | +++ |
| EM | F | 62 | 15 y | Phl, HU, Bu | nd | PV | +++ |
| HL | M | 62 | 2 y | Phl, HU | 400 | PV | +++ |
| HH | M | 65 | < 1 y | Phl | 76 | PV | +++ |
| RH | M | 54 | 4 y | Phl | nd | PV | +++ |
| RS | F | 38 | 14 y | Phl | nd | PV | +++ |
| FB | M | 74 | 10 y | Phl | nd | PV | +++ |
| EW | F | 62 | 16 y | Phl, HU, IFN-α | 192 | PV | +++ |
| SH | M | 43 | 6 y | Phl, ASS | nd | PV | +++ |
| DJ | M | 40 | 6 y | Phl | 105 | PV | +++ |
| IP | F | 60 | 3 y | Phl | 176 | PV | +++ |
| WA | F | 46 | 37 y | Phl | nd | PV | +++ |
| HS | F | 64 | 1 y | HU | 179 | PV | +++ |
| MT | M | 58 | 8 y | Phl, HU | 163 | PV | +++ |
| FW | M | 69 | 10 y | IFN-α | 134 | ET | +++ |
| RW | F | 39 | 4 y | HU, ASS Anag | 33 | ET | + |
| EW | M | 63 | 6 y | HU | nd | ET | − |
| LH | M | 60 | 9 y | HU | nd | ET | − |
| MS | F | 50 | 1 y | HU | 123 | ET | − |
| HZ | F | 73 | 11 y | HU, ASS IFN-α | 2 | ET | − |
| HUB | M | 60 | 12 y | HU, AraC | nd | CML | − |
| BE | F | 80 | 3 y | HU | nd | CML | − |
| RW | F | 54 | 1 y | None | nd | CML | − |
| XR | M | 44 | at dx | None | nd | CML | − |
| HJH | M | 64 | < 1 y | Erythrocyte transfusion | nd | IMF | + |
| VW | M | 21 | 2 y | Multiple polychemo Allo BMT | nd | AML FAB M4 | − |
| FK | F | 78 | at dx | None | nd | AML FAB M1 | − |
| EF | M | 45 | < 1 y | Allo BMT | nd | AML FAB M5 | − |
| VF | M | 61 | at dx | None | nd | AML FAB M5b | − |
| UM | F | 56 | at dx | None | nd | AML FAB M1 | − |
| JMPM | M | 41 | at dx | None | nd | Erythrocytosis | − |
| RB | M | 46 | at dx | None | nd | Erythrocytosis | − |
| JP | M | 78 | at dx | None | nd | Erythrocytosis | − |
| YK | M | 52 | at dx | None | nd | Erythrocytosis | − |
| Patient . | Sex . | Age (y) . | Duration of Disease . | Treatment . | LAP (normal: 10-100) . | Diagnosis . | PRV-1 Expression . |
|---|---|---|---|---|---|---|---|
| WZ | F | 75 | 2 y | Phl | nd | PV | +++ |
| EH | F | 68 | 12 y | Phl, HU, Bu | 84 | PV | +++ |
| HJL | M | 59 | 4 y | Phl | 200 | PV | +++ |
| SR | M | 62 | 7 y | Phl | nd | PV | +++ |
| UW | M | 65 | 10 y | Phl, HU | nd | PV | +++ |
| UD | F | 66 | < 1 y | Phl | 264 | PV | +++ |
| EM | F | 62 | 15 y | Phl, HU, Bu | nd | PV | +++ |
| HL | M | 62 | 2 y | Phl, HU | 400 | PV | +++ |
| HH | M | 65 | < 1 y | Phl | 76 | PV | +++ |
| RH | M | 54 | 4 y | Phl | nd | PV | +++ |
| RS | F | 38 | 14 y | Phl | nd | PV | +++ |
| FB | M | 74 | 10 y | Phl | nd | PV | +++ |
| EW | F | 62 | 16 y | Phl, HU, IFN-α | 192 | PV | +++ |
| SH | M | 43 | 6 y | Phl, ASS | nd | PV | +++ |
| DJ | M | 40 | 6 y | Phl | 105 | PV | +++ |
| IP | F | 60 | 3 y | Phl | 176 | PV | +++ |
| WA | F | 46 | 37 y | Phl | nd | PV | +++ |
| HS | F | 64 | 1 y | HU | 179 | PV | +++ |
| MT | M | 58 | 8 y | Phl, HU | 163 | PV | +++ |
| FW | M | 69 | 10 y | IFN-α | 134 | ET | +++ |
| RW | F | 39 | 4 y | HU, ASS Anag | 33 | ET | + |
| EW | M | 63 | 6 y | HU | nd | ET | − |
| LH | M | 60 | 9 y | HU | nd | ET | − |
| MS | F | 50 | 1 y | HU | 123 | ET | − |
| HZ | F | 73 | 11 y | HU, ASS IFN-α | 2 | ET | − |
| HUB | M | 60 | 12 y | HU, AraC | nd | CML | − |
| BE | F | 80 | 3 y | HU | nd | CML | − |
| RW | F | 54 | 1 y | None | nd | CML | − |
| XR | M | 44 | at dx | None | nd | CML | − |
| HJH | M | 64 | < 1 y | Erythrocyte transfusion | nd | IMF | + |
| VW | M | 21 | 2 y | Multiple polychemo Allo BMT | nd | AML FAB M4 | − |
| FK | F | 78 | at dx | None | nd | AML FAB M1 | − |
| EF | M | 45 | < 1 y | Allo BMT | nd | AML FAB M5 | − |
| VF | M | 61 | at dx | None | nd | AML FAB M5b | − |
| UM | F | 56 | at dx | None | nd | AML FAB M1 | − |
| JMPM | M | 41 | at dx | None | nd | Erythrocytosis | − |
| RB | M | 46 | at dx | None | nd | Erythrocytosis | − |
| JP | M | 78 | at dx | None | nd | Erythrocytosis | − |
| YK | M | 52 | at dx | None | nd | Erythrocytosis | − |
M indicates male; F, female; age: age at time of blood sampling; duration of disease, expressed in years (y) at time of blood sampling; at dx, at the time of diagnosis; treatment, treatment prior to or at the time of blood sampling; Phl, phlebotomy; HU, hydroxyurea; ASS, salicylic acid (aspirin); Bu, busulfan; INF-α, interferon alpha; Anag, anagrelide; AraC, cytosine arabinoside; Allo BMT, allogenic bone marrow transplant; LAP, leukocyte alkaline phosphatase, normal range 10-100; nd, not determined; PV, polycythemia vera; ET, essential thrombocythemia; CML, chronic myelogenous leukemia; AML, acute myelogenous leukemia; erythrocytosis, secondary erythrocytosis; PRV-1 expression: +++ indicates strong PRV-1 expression, + indicates weak PRV-1 expression, − indicates no PRV-1 expression.